Insights from 2023 ESMO Annual Meeting
ESMO 2023 Insights: "innovaTV 301/ENGOT-cx12/GOG-3057 Study - Tisotumab Vedotin vs. Investigator’s Choice of Chemo in 2L/3L Recurrent or Metastatic Cervical Cancer"
By
Insights from 2023 ESMO Annual Meeting
FEATURING
Susana Banerjee
By
Insights from 2023 ESMO Annual Meeting
FEATURING
Susana Banerjee
Comments 0
Login to view comments.
Click here to Login
